Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy

doi:10.4251/wjgo.v16.i2.273

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1862)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

1355

Figures (1-2)

102

Tables (1-4)

100

Sum=1623

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

113

Sum=183

Feb 15, 2024 (publication date) through May 15, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Oncol. Feb 15, 2024; 16(2): 273-286
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.273

Open in New Tab Full Size Figure Download Figure

Figure 1 Schedule of systemic liver cancer treatment approved by the United States Food and Drug Administration.

Open in New Tab Full Size Figure Download Figure

Figure 2 Concepts of hepatocellular carcinoma immunotherapy, immunotherapy combination therapy, and related trials in recent years. HCC: Hepatocellular carcinoma; CAR-T: Chimeric antigen receptor T cells; VEGF: Vasoactive endothelial growth factor.

Citation: Pan D, Liu HN, Qu PF, Ma X, Ma LY, Chen XX, Wang YQ, Qin XB, Han ZX. Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy. World J Gastrointest Oncol 2024; 16(2): 273-286
URL: https://www.wjgnet.com/1948-5204/full/v16/i2/273.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i2.273